Mitochondrial nutrients: Reducing mitochondrial decay to delay or treat cognitive dysfunction, alzheimer’s disease, and parkinson’s disease

Oxidative Stress and Age-Related Neurodegeneration

Volumn , Issue , 2005, Pages 59-106

  Liu, Jiankang ^a   Ames, Bruce N ^b  

^a Children's Hospital of Oakland Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84939893630     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (283)

1. Ames BN, Liu J, Atamna H, and Hagen TM. Delaying the mitochondrial decay of aging in the brain. Clin Neurosci Res., 2003; 2: 331-338.
2. Ames BN, Shigenaga MK, and Hagen TM. Mitochondrial decay in aging. Biochim Biophys Acta, 1995; 1271: 165-170.
3. Ames BN, Shigenaga MK, and Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA, 1993; 90: 7915-7922.
4. Shigenaga MK, Hagen TM, and Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA, 1994; 91: 10771-10778.
5. Beckman KB and Ames BN. The free radical theory of aging matures. Physiol Rev, 1998; 78: 547-581.
6. Harman D Increasing Healthy Life Span, Vol. 959. New York: The New York Academy of Sciences, 2002.
7. Roubertoux PL, Sluyter F, Carlier M, Marcet B, Maarouf-Veray F, Cherif C, Marican C, Arrechi P, Godin F, Jamon M, Verrier B, and Cohen-Salmon C. Mitochondrial DNA modifies cognition in interaction with the nuclear genome and age in mice. Nat Genet, 2003; 35: 65-69.
8. Tritschler HJ, Packer L, and Medori R. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Biochem Mol Biol Int, 1994; 34: 169-181.
9. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol, 1992; 31: 119-130.
10. Liu J and Mori A. Stress, aging, and brain oxidative damage. Neurochem Res, 1999; 24: 1479-1497.
11. Albers DS and Beal MF. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm. 2000; 59(Suppl.): 133-154.
12. Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, Gasimov EK, Vinters HV, Perry G, LaManna JC, and Friedland RP. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer’s disease. Brain Pathol, 2002; 12: 21-35.
13. Rao AV and Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci, 2002; 5: 291-309.
14. Smith MA, Perry G, and Pryor WA. Causes and consequences of oxidative stress in Alzheimer’s disease. Free Radic Biol Med, 2002; 32: 1049.
15. Perry G, Nunomura A, Friedlich AL, Boswell MV, et al., Factors controlling oxidative damage in Alzheimer disease: metals and mitochondria. In: Yoshikawa T, Toyokuni S, Yamamoto Y, and Naito Y, eds. Free Radicals in Chemistry, Biology and Medicine, OICA International, 2000: 417-423.
16. Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc, 1972; 20: 145-147.
17. Hagen TM, Ingersoll RT, Wehr CM, Lykkesfeldt J, Vinarsky V, Bartholomew JC, Song MH, and Ames BN. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA, 1998; 95: 9562-9566.
18. Sohal RS and Weindruch R. Oxidative stress, caloric restriction, and aging. Science, 1996; 273: 59-63.
19. Stadtman ER and Levine RL. Protein oxidation. Ann NY Acad Sci, 2000; 899: 191-208.
20. Chen JJ and Yu BP. Alterations in mitochondrial membrane fluidity by lipid peroxidation products. Free Radic Biol Med, 1994; 17: 411-418.
21. Choi JH and Yu BP. Brain synaptosomal aging: free radicals and membrane fluidity. Free Radic Biol Med, 1995; 18: 133-139.
22. Paradies G, Ruggiero FM, Petrosillo G, Gadaleta MN, and Quagliariello E. Effect of aging and acetyl-L-carnitine on the activity of cytochrome oxidase and adenine nucleotide translocase in rat heart mitochondria. FEBS Lett, 1994; 350: 213-215.
23. Ames BN, Elson-Schwab I, and Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. Am J Clin Nutr, 2002; 75: 616-658.
24. Feuers RJ. The effects of dietary restriction on mitochondrial dysfunction in aging. Ann NY Acad Sci, 1998; 854: 192-201.
25. Liu J, Killilea DW, and Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci USA, 2002; 99: 1876-1881.
26. Coimbra CG and Junqueira VB. High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson’s disease patients. Braz J Med Biol Res, 2003; 36: 1409-1417.
27. Ebadi M, Govitrapong P, Sharma S, Muralikrishnan D, Shavali S, Pellett L, Schafer R, Albano C, and Eken J. Ubiquinone (coenzyme Q10) and mitochondria in oxidative stress of parkinson’s disease. Biol Signals Recept, 10: 2001; 224-253.
28. Gutteridge JMC. Thiobarbituric acid-reactivity following iron-dependent free-rad-icals damage to amino acids and carbohydrates. FEBS Lett, 1981; 128: 343-346.
29. Bourdon E and Blache D. The importance of proteins in defense against oxidation. Antioxid Redox Signal, 2001; 3: 293-311.
30. Fu S, Hick LA, Sheil MM, and Dean RT. Structural identification of valine hydroperoxides and hydroxides on radical-damaged amino acid, peptide, and protein molecules. Free Radic Biol Med, 1995; 19: 281-292.
31. Morin B, Bubb WA, Davies MJ, Dean RT, and Fu S. 3-Hydroxylysine, a potential marker for studying radical-induced protein oxidation. Chem Res Toxicol, 1998; 11: 1265-1273.
32. Stadtman ER and Berlett BS. Fenton chemistry. Amino acid oxidation. J Biol Chem, 1991; 266: 17201-1711.
33. Stadtman ER. Protein oxidation and aging. Science, 1992; 257: 1220-1224.
34. Fucci L, Oliver CN, Coon MJ, and Stadtman ER. Inactivation of key metabolic enzymes by mixed-function oxidation reactions: possible implication in protein turnover and ageing. Proc Natl Acad Sci USA, 1983; 80: 1521-1525.
35. Esterbauer H, Schaur RJ, and Zöllner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med, 1991; 11: 81-128.
36. Humphries KM and Szweda LI. Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2- nonenal. Biochemistry, 1998; 37: 15835-15841.
37. Humphries KM, Yoo Y, and Szweda LI. Inhibition of NADH-linked mitochondrial respiration by 4-hydroxy-2- nonenal. Biochemistry, 1998; 37: 552-557.
38. Butterfield DA and Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: Technology and application to the study of neurodegenerative disorders. Amino Acids, 2003; 25: 419-425.
39. Halliwell B and Gutteridge JMC. Free Radicals in Biology and Medicine, 3rd ed. New York:Oxford University Press, 1999
40. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, and Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J Neurochem, 2003; 85: 1394-1401.
41. Jiang Q, Lykkesfeldt J, Shigenaga MK, Shigeno ET, Christen S, and Ames BN. Gamma-tocopherol supplementation inhibits protein nitration and ascorbate oxidation in rats with inflammation. Free Radic Biol Med, 2002; 33: 1534-1542.
42. Jiang Q and Ames BN. Gamma-tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J, 2003; 17: 816-822.
43. Wolff SP, Jiang ZY, and Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med, 1991, 10: 339-352.
44. Hallen A. Accumulation of insoluble protein and aging. Biogerontology, 2002; 3: 307-315.
45. Cuervo AM and Dice JF. When lysosomes get old. Exp Gerontol, 2000; 35: 119-131.
46. Grune T, Reinheckel T, Li R, North JA, and Davies KJ. Proteasome-dependent turnover of protein disulfide isomerase in oxidatively stressed cells. Arch Biochem Biophys, 2002; 397: 407-413.
47. Grune T, Shringarpure R, Sitte N, and Davies K. Age-related changes in protein oxidation and proteolysis in mammalian cells. J Gerontol A: Biol Sci Med Sci, 2001; 56: B459-B467.
48. Sitte N, Merker K, Von Zglinicki T, Davies KJ, and Grune T. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part II—aging of nondividing cells. FASEB J, 2000; 14: 2503-2510.
49. Sitte N, Merker K, von Zglinicki T, and Grune T. Protein oxidation and degradation during proliferative senescence of human MRC-5 fibroblasts. Free Radic Biol Med, 2000; 28: 701-708.
50. Sitte N, Merker K, Von Zglinicki T, Grune T, and Davies KJ. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I — effects of proliferative senescence. FASEB J, 2000; 14: 2495-2502.
51. Munch G, Kuhla B, Luth HJ, Arendt T, and Robinson SR. Anti-AGEing defences against Alzheimer’s disease. Biochem Soc Trans, 2003; 31: 1397-1399.
52. Uttenthal LO, Alonso D, Fernandez AP, Campbell RO, Moro MA, Leza JC, Lizasoain I, Esteban FJ, Barroso JB, Valderrama R, Pedrosa JA, Peinado MA, Serrano J, Richart A, Bentura ML, Santacana M, Martinez-Murillo R, and Rodrigo J. Neuronal and inducible nitric oxide synthase and nitrotyrosine immunoreactivities in the cerebral cortex of the aging rat. Microsc Res Tech, 1998; 43: 75-88.
53. Good PF, Werner P, Hsu A, Olanow CW, and Perl DP. Evidence of neuronal oxidative damage in Alzheimer’s disease. Am J Pathol, 1996; 149: 21-28.
54. Song X, Bao M, Li D, and Li YM. Advanced glycation in D-galactose induced mouse aging model. Mech Ageing Dev, 1999; 108: 239-251.
55. Teillet L, Ribiere P, Gouraud S, Bakala H, and Corman B. Cellular signaling, AGE accumulation and gene expression in hepatocytes of lean aging rats fed ad libitum or food-restricted. Mech Ageing Dev, 2002; 123: 427-439.
56. Teillet L, Verbeke P, Gouraud S, Bakala H, Borot-Laloi C, Heudes D, Bruneval P, and Corman B. Food restriction prevents advanced glycation end product accumulation and retards kidney aging in lean rats. J Am Soc Nephrol, 2000; 11: 1488-1497.
57. Cadenas E and Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med, 2000; 29: 222-230.
58. Hrelia S, Celadon M, Rossi CA, Biagi PL, and Bordoni A. Delta-6-desaturation of linoleic and alpha-linolenic acids in aged rats: a kinetic analysis. Biochem Int, 1990; 22: 659-667.
59. Hossain MA, Masserano JM, and Weiner N. Age-related changes in tetrahydro-biopterin and GTP-cyclohydrolase activity in the brain and adrenal gland of rats. Neurobiol Aging, 1995; 16: 627-632.
60. Hussain AM and Mitra AK. Effect of aging on tryptophan hydroxylase in rat brain: implications on serotonin level. Drug Metab Dispos, 2000; 28: 1038-1042.
61. Pradhan SN. Central neurotransmitters and aging. Life Sci, 1980; 26: 1643-1656.
62. Stadtman ER, Moskovitz J, and Levine RL. Oxidation of methionine residues of proteins: biological consequences. Antioxid Redox Signal, 2003; 5: 577-582.
63. Stadtman ER and Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids, 2003; 25: 207-218.
64. Grundman M and Delaney P. Antioxidant strategies for Alzheimer’s disease. Proc Nutr Soc, 2002; 61: 191-202.
65. McDaniel MA, Maier SF, and Einstein GO. “Brain-specific” nutrients: a memory cure? Nutrition, 2003; 19: 957-975.
66. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson’s disease. Ann Neurol, 2003; 53(Suppl 3): S39-S47; discussion S47-S48.
67. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, and Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer’s disease. J Nutr Biochem, 2002; 13: 444.
68. Butterfield DA, Castegna A, Drake J, Scapagnini G, and Calabrese V. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr Neurosci, 2002; 5: 229-239.
69. Marriage B, Clandinin MT, and Glerum DM. Nutritional cofactor treatment in mitochondrial disorders. J Am Diet Assoc, 2003; 103: 1029-1038.
70. Baker SK and Tarnopolsky MA. Targeting cellular energy production in neurological disorders. Expert Opin Investig Drugs, 2003; 12: 1655-1679.
71. Black MM. Micronutrient deficiencies and cognitive functioning. J Nutr, 2003; 133: 3927S-3931S.
72. Price MC. Longevity Report 91: The role of enzymic cofactors in aging. www.quantium.cwe.net/lr91.htm#_Toc22709815, 2002.
73. Lee L, Kang SA, Lee HO, Lee BH, Park JS, Kim JH, Jung IK, Park YJ, and Lee JE. Relationships between dietary intake and cognitive function level in Korean elderly people. Public Health, 2001; 115: 133-138.
74. La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, and Garry PJ. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. Am J Clin Nutr, 1997; 65: 20-29.
75. Walter PB, Knutson MD, Paler-Martinez A, Lee S, Xu Y, Viteri FE, and Ames BN. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. Proc Natl Acad Sci USA, 2002; 99: 2264-2269.
76. Benton D. Micro-nutrient supplementation and the intelligence of children. Neurosci Biobehav Rev, 2001; 25: 297-309.
77. Tamura T, Goldenberg RL, Hou J, Johnston KE, Cliver SP, Ramey SL, and Nelson KG. Cord serum ferritin concentrations and mental and psychomotor development of children at five years of age. J Pediatr, 2002; 140: 165-170.
78. Beard JL and Connor JR. Iron status and neural functioning. Annu Rev Nutr, 2003; 23: 41-58.
79. Gordon N. Iron deficiency and the intellect. Brain Dev, 2003; 25: 3-8.
80. Grantham-McGregor S and Ani C. A review of studies on the effect of iron deficiency on cognitive development in children. J Nutr, 2001; 131: 649S-666S; discussion 666S-668S.
81. Atamna H, Liu J, and Ames BN. Heme deficiency selectively interrupts assembly of mitochondrial complex IV in human fibroblasts: revelance to aging. J Biol Chem, 2001; 276: 48410-48416.
82. Atamna H. Heme, iron, and the mitochondrial decay of ageing. Ageing Res Rev, 2004; 3: 303-318.
83. Atamna H, Walter PW, and Ames BN. The role of heme and iron-sulfur clusters in mitochondrial biogenesis, maintenance, and decay with age. Arch Biochem Biophys, 2002; 397: 345-353.
84. Atamna H, Killilea DW, Killilea AN, and Ames BN. Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. Proc Natl Acad Sci USA, 2002; 99: 14807-14812.
85. Ho E and Ames BN. Low intracellular zinc induces oxidative DNA damage, disrupts p53, NFkB, and AP1 DNA-binding, and affects DNA repair in a rat glioma cell line. Proc Natl Acad Sci USA, 2002; 99: 16770-16775.
86. Ho E, Courtemanche C, and Ames BN. Zinc deficiency induces oxidative DNA damage and increases p53 expression in human lung fibroblasts. J Nutr, 2003; 133: 2543-2548.
87. Sandstead HH, Frederickson CJ, and Penland JG. History of zinc as related to brain function. J Nutr, 2000; 130: 496S-502S.
88. Bhatnagar S and Taneja S. Zinc and cognitive development. Br J Nutr, 2001; 85(Suppl 2): S139-S145.
89. Rossi L, Lippe G, Marchese E, De Martino A, Mavelli I, Rotilio G, and Ciriolo MR. Decrease of cytochrome c oxidase protein in heart mitochondria of copper-deficient rats. Biometals, 1998; 11: 207-212.
90. Steffens GC, Biewald R, and Buse G. Cytochrome c oxidase is a three-copper, two-heme-A protein. Eur J Biochem, 1987; 164: 295-300.
91. Williams DM, Kennedy FS, and Green BG. The effect of iron substrate on mitochondrial haem synthesis in copper deficiency. Br J Nutr, 1985; 53: 131-136.
92. Keyhani E and Keyhani J. Identification of porphyrin present in apo-cytochrome C oxidase of copper-deficient yeast cells. Biochim Biophys Acta, 1980; 633: 211-227.
93. Nakayama K, Takasawa A, Terai I, Okui T, Ohyama T, and Tamura M. Spontaneous porphyria of the Long-evans cinnamon rat: an animal model of Wilson’s disease. Arch Biochem Biophys, 2000; 375: 240-250.
94. Plesofsky-Vig N Pantothenic Acid. 7 ed. New York: ILSI Press, 1996.
95. Brambl R and Plesofsky-Vig N. Pantothenate is required in Neurospora crassa for assembly of subunit peptides of cytochrome c oxidase and ATPase/ATP synthase. Proc Natl Acad Sci USA, 1986; 83: 3644-3648.
96. Scholnick PL, Hammaker LE, and Marver HS. Soluble -aminolevulinic acid synthetase of rat liver. II. Studies related to the mechanism of enzyme action and hemin inhibition. J Biol Chem, 1972; 247: 4132-4137.
97. Wakimoto P and Block G. Dietary intake, dietary patterns, and changes with age: an epidemiological perspective. J Gerontol A: Biol Sci Med Sci, 2001; 56(Spec No2): 65-80.
98. Mock DM, Henrich CL, Carnell N, and Mock NI. Indicators of marginal biotin deficiency and repletion in humans: validation of 3-hydroxyisovaleric acid excretion and a leucine challenge. Am J Clin Nutr, 2002; 76: 1061-1068.
99. Mock DM, Quirk JG, and Mock NI. Marginal biotin deficiency during normal pregnancy. Am J Clin Nutr, 2002; 75: 295-299.
100. Mock DM Biotin. Washington, DC:International Life Sciences Institute, 1989.
101. Higdon J. An Evidence-Based Approach to Vitamins and Minerals. New York:Thieme, 2003.
102. Heroux M, Raghavendra RVL, Lavoie J, Richardson JS, and Butterworth RF. Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer’s disease. Metab Brain Dis, 1996, 11: 81-88.
103. Harman D. The aging process. Basic Life Sci, 1988; 49: 1057-1065.
104. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, Wilson PW, and Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med, 2002; 346: 476-483.
105. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, and Mattson MP. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer’s disease. J Neurosci, 2002; 22: 1752-1762.
106. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, and Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem, 2002; 80: 101-110.
107. Joseph JA, Denisova N, Fisher D, Shukitt-Hale B, Bickford P, Prior R, and Cao G. Membrane and receptor modifications of oxidative stress vulnerability in aging. Nutritional considerations. Ann NY Acad Sci, 1998; 854: 268-276.
108. Ames BN, Cathcast R, Schwiers E, and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant — and free radical — caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA, 1981, 78: 6858-6862.
109. Morris MC, Evans DA, Bienias JL, Scherr PA, Tangney CC, Hebert LE, Bennett DA, Wilson RS, and Aggarwal N. Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline. J Neurol Neurosurg Psychiatry, 2004; 75: 1093-1099.
110. 12-dependent methionine synthetase on the subcellular distribution of folate coenzymes in rat liver. Arch Biochem Biophys, 1989; 270: 729-733.
111. Carl GF, Hudson FZ, and McGuire BS, Jr. Formyltetrahydrofolates associated with mitochondria have longer polyglutamate chains than the methyltetrahydrofolates associated with cytoplasm in rat brain. J Nutr, 1996; 126: 3077-3082.
112. Mattson MP and Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci, 2003; 26: 137-146.
113. Bjorke MAL and Ueland PM. Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to adolescence. Am J Clin Nutr, 2003; 78: 7-21.
114. Miller AL. The methionine-homocysteine cycle and its effects on cognitive diseases. Altern Med Rev, 2003; 8: 7-19.
115. Frick KM, Stearns NA, Pan JY, and Berger-Sweeney J. Effects of environmental enrichment on spatial memory and neurochemistry in middle-aged mice. Learn Mem, 2003; 10: 187-198.
116. Reynolds EH. Folic acid, ageing, depression, and dementia. BMJ, 2002; 324: 1512-1515.
117. Totland GK, Madsen L, Klementsen B, Vaagenes H, Kryvi H, Froyland L, Hexeberg S, and Berge RK. Proliferation of mitochondria and gene expression of carnitine palmitoyltransferase and fatty acyl-CoA oxidase in rat skeletal muscle, heart and liver by hypolipidemic fatty acids. Biol Cell, 2000; 92: 317-329.
118. Ishiguro J, Tada T, Ogihara T, Ohzawa N, Murakami K, and Kosuzume H. Metabolic disposition of ethyl eicosapentaenoate and its metabolites in rats and dogs. J Pharmacobiodyn, 1988; 11: 251-261.
119. Madsen L, Rustan AC, Vaagenes H, Berge K, Dyroy E, and Berge RK. Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference. Lipids, 1999; 34: 951-963.
120. Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog Lipid Res, 1985; 24: 69-176.
121. Giusto NM, Pasquare SJ, Salvador GA, Castagnet PI, Roque ME, and Ilincheta de Boschero MG. Lipid metabolism in vertebrate retinal rod outer segments. Prog Lipid Res, 2000; 39: 315-391.
122. Salem N, Jr., Litman B, Kim HY, and Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids, 2001; 36: 945-959.
123. Salem N, Jr., Wegher B, Mena P, and Uauy R. Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. Proc Natl Acad Sci USA, 1996; 93: 49-54.
124. Uauy R, Mena P, Wegher B, Nieto S, and Salem N, Jr. Long chain polyunsaturated fatty acid formation in neonates: effect of gestational age and intrauterine growth. Pediatr Res, 2000; 47: 127-135.
125. Uauy R and Peirano P. Breast is best: human milk is the optimal food for brain development. Am J Clin Nutr, 1999; 70: 433-434.
126. Crawford M. Placental delivery of arachidonic and docosahexaenoic acids: implications for the lipid nutrition of preterm infants. Am J Clin Nutr, 2000; 71: 275S-284S.
127. Haggarty P. Effect of placental function on fatty acid requirements during pregnancy. Eur J Clin Nutr, 2004; 58: 1559-1570.
128. Anderson JW, Johnstone BM, and Remley DT. Breast-feeding and cognitive development: a meta-analysis. Am J Clin Nutr, 1999; 70: 525-535.
129. Jain A, Concato J, and Leventhal JM. How good is the evidence linking breastfeeding and intelligence? Pediatrics, 2002; 109: 1044-1053.
130. Drane DL and Logemann JA. A critical evaluation of the evidence on the association between type of infant feeding and cognitive development. Paediatr Perinat Epidemiol, 2000; 14: 349-356.
131. Rey J. Breastfeeding and cognitive development. Acta Paediatr Suppl, 2003; 92:11-18.
132. Jacobson SW and Jacobson JL. Breastfeeding and IQ: evaluation of the socio-environmental confounders. Acta Paediatr, 2002; 91: 258-260.
133. Moriguchi T, Greiner RS, and Salem N, Jr. Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. J Neurochem, 2000; 75: 2563-2573.
134. Ng KF and Innis SM. Behavioral responses are altered in piglets with decreased frontal cortex docosahexaenoic acid. J Nutr, 2003; 133: 3222-3227.
135. Moriguchi T and Salem N, Jr. Recovery of brain docosahexaenoate leads to recovery of spatial task performance. J Neurochem, 2003; 87: 297-309.
136. Sugimoto Y, Taga C, Nishiga M, Fujiwara M, Konishi F, Tanaka K, and Kamei C. Effect of docosahexaenoic acid-fortified Chlorella vulgaris strain CK22 on the radial maze performance in aged mice. Biol Pharm Bull, 2002; 25: 1090-1092.
137. Neuringer M, Connor WE, Lin DS, Barstad L, and Luck S. Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci USA, 1986; 83: 4021-4025.
138. Reisbick S, Neuringer M, Gohl E, Wald R, and Anderson GJ. Visual attention in infant monkeys: effects of dietary fatty acids and age. Dev Psychol, 1997; 33: 387-395.
139. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, and Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids, 2000; 35: 1305-1312.
140. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, and Schneider J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol, 2003; 60: 940-946.
141. Kyle DJ, Schaefer E, Patton G, and Beiser A. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer’s dementia. Lipids, 1999; 34(Suppl.): S245.
142. Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR, and Burgess JR. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr, 1995; 62: 761-768.
143. Visioli F, Rise P, Barassi MC, Marangoni F, and Galli C. Dietary intake of fish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids, 2003; 38: 415-418.
144. Simopoulos AP. n-3 fatty acids and human health: defining strategies for public policy. Lipids, 2001; 36(Suppl.): S83-S89.
145. Blusztajn JK. Choline, a vital amine. Science, 1998; 281: 794-795.
146. Zeisel SH, Da Costa KA, Franklin PD, Alexander EA, Lamont JT, Sheard NF, and Beiser A. Choline, an essential nutrient for humans. FASEB J, 1991; 5: 2093-2098.
147. Zeisel SH. Choline and human nutrition. Annu Rev Nutr, 1994; 14: 269-296.
148. Whyte J, Harrison R, Lunt GG, and Wonnacott S. Subcellular fractionation and distribution of cholinergic binding sites in fetal human brain. Neurochem Res, 1986; 11: 1011-1023.
149. Schlame M, Rustow B, and Kunze D. Synthesis of phosphatidylcholine and phos-phatidylglycerol in rat lung mitochondria. Mol Cell Biochem, 1989; 85: 115-122.
150. D’Souza C, Clarke JT, Cook HW, and Spence MW. Phospholipid transfer proteinmediated incorporation and subcellular distribution of exogenous phosphatidylcholine and sphingomyelin in cultured neuroblastoma cells. Biochim Biophys Acta, 1983; 729: 1-8.
151. Holmes-McNary MQ, Loy R, Mar MH, Albright CD, and Zeisel SH. Apoptosis is induced by choline deficiency in fetal brain and in PC12 cells. Brain Res Dev Brain Res, 1997; 101: 9-16.
152. Yen CL, Mar MH, Meeker RB, Fernandes A, and Zeisel SH. Choline deficiency induces apoptosis in primary cultures of fetal neurons. FASEB J, 2001; 15: 1704-1710.
153. Meck WH and Williams CL. Metabolic imprinting of choline by its availability during gestation: implications for memory and attentional processing across the lifespan. Neurosci Biobehav Rev, 2003; 27: 385-399.
154. McKeon-O’Malley C, Siwek D, Lamoureux JA, Williams CL, and Kowall NW. Prenatal choline deficiency decreases the cross-sectional area of cholinergic neurons in the medial septal nucleus. Brain Res, 2003; 977: 278-283.
155. Pyapali GK, Turner DA, Williams CL, Meck WH, and Swartzwelder HS. Prenatal dietary choline supplementation decreases the threshold for induction of longterm potentiation in young adult rats. J Neurophysiol, 1998; 79: 1790-1796.
156. Mellott TJ, Williams CL, Meck WH, and Blusztajn JK. Prenatal choline supplementation advances hippocampal development and enhances MAPK and CREB activation. FASEB J, 2004; 18: 545-547.
157. Zeisel SH. Nutritional importance of choline for brain development. J Am Coll Nutr, 2004; 23: 621S-626S.
158. Aliev G. Vascular hypoperfusion, mitochondrial failure and oxidative stress in Alzheimer Disease. Proc Indian Natl Sci Acad, 2003; B69: 209-238.
159. Cash AD, Perry G, Ogawa O, Raina AK, Zhu X, and Smith MA. Is Alzheimer’s disease a mitochondrial disorder? Neuroscientist, 2002; 8: 489-496.
160. Corral DM, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, Graham BH, and Wallace DC. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics, 1994; 23: 471-476.
161. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, and Smith MA. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci, 2001; 21: 3017-3023.
162. Mecocci P, MacGarvey U, and Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol, 1994; 36: 747-751.
163. Perry G, Nunomura A, Hirai K, Zhu X, Perez M, Avila J, Castellani RJ, Atwood CS, Aliev G, Sayre LM, Takeda A, and Smith MA. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer’s and other neurodegenerative diseases? Free Radic Biol Med, 2002; 33: 1475-1479.
164. Coskun PE, Beal MF, and Wallace DC. Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA, 2004; 101: 10726-10731.
165. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, and Markesbery WR. Protein oxidation in the brain in Alzheimer’s disease. Neuroscience, 2001; 103: 373-383.
166. Betarbet R, Sherer TB, and Greenamyre JT. Animal models of Parkinson’s disease. Bioessays, 2002; 24: 308-318.
167. Ebadi M, Srinivasan SK, and Baxi MD. Oxidative stress and antioxidant therapy in Parkinson’s disease. Prog Neurobiol, 1996; 48: 1-19.
168. Kondo T. Parkinson’s disease and free radicals. Mechanism of neurodegeneration and neuroprotection. Ann NY Acad Sci, 1996; 786: 206-216.
169. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, and Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem, 1990; 54: 823-827.
170. de Grey ADJ The Mitochondrial Free Radical Theory of Aging. Georgetown, Texas:Molecular Biology Intelligence Unit, R.G. Landers Company, 1999.
171. Parker WD Jr., Boyson SJ, and Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol, 1989; 26: 719-723.
172. Langston JW. Current theories on the cause of Parkinson’s disease. J Neurol Neurosurg Psychiatry, 1989; Suppl: 13-17.
173. Glinka Y, Tipton KF, and Youdim MB. Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxam-ine. Eur J Pharmacol, 1998; 351: 121-129.
174. Liu Y, Fiskum G, and Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem, 2002; 80: 780-787.
175. Rosler M, Retz W, Thome J, and Riederer P. Free radicals in Alzheimer’s dementia: currently available therapeutic strategies. J Neural Transm Suppl, 1998; 54: 211-219.
176. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, and Breitner JC. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol, 2004; 61: 82-88.
177. Rutten BP, Steinbusch HW, Korr H, and Schmitz C. Antioxidants and Alzheimer’s disease: from bench to bedside (and back again). Curr Opin Clin Nutr Metab Care, 2002; 5: 645-651.
178. Giacobini E. Cholinergic function and Alzheimer’s disease. Int J Geriatr Psychiatry, 2003; 18: S1-S5.
179. Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer’s disease. Clin Ther, 2004; 26: 615-630.
180. Buyukuysal RL, Ulus IH, Aydin S, and Kiran BK. 3,4-Diaminopyridine and choline increase in vivo acetylcholine release in rat striatum. Eur J Pharmacol, 1995; 281: 179-185.
181. Rao VL, Richardson JS, and Butterworth RF. Decreased activities of thiamine diphosphatase in frontal and temporal cortex in Alzheimer’s disease. Brain Res, 1993; 631: 334-336.
182. Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, and Perrino P. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol, 1988; 45: 836-840.
183. Butterworth RF and Besnard AM. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer’s disease. Metab Brain Dis, 1990; 5: 179-184.
184. Blass JP, Gleason P, Brush D, DiPonte P, and Thaler H. Thiamine and Alzheimer’s disease. A pilot study. Arch Neurol, 1988; 45: 833-835.
185. Meador K, Loring D, Nichols M, Zamrini E, Rivner M, Posas H, Thompson E, and Moore E. Preliminary findings of high-dose thiamine in dementia of Alzheimer’s type. J Geriatr Psychiatry Neurol, 1993; 6: 222-229.
186. Mimori Y, Katsuoka H, and Nakamura S. Thiamine therapy in Alzheimer’s disease. Metab Brain Dis, 1996; 11: 89-94.
187. Rodriguez-Martin JL, Lopez-Arrieta JM, and Qizilbash N. Thiamine for Alzheimer’s disease. Cochrane Database Syst Rev, 2000; 2: CD001498.
188. Kirsch M and De Groot H. NAD(P)H, a directly operating antioxidant? FASEB J, 2001;15:1569-1574.
189. Birkmayer JG. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci, 1996; 26: 1-9.
190. Rainer M, Kraxberger E, Haushofer M, Mucke HA, and Jellinger KA. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. J Neural Transm, 2000; 107: 1475-1481.
191. Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, and Ulm G. Diet and Parkinson’s disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology, 1996; 47: 644-650.
192. Birkmayer W and Birkmayer GJ. Strategy and tactic of modern Parkinson therapy. Acta Neurol Scand Suppl, 1989; 126: 63-66.
193. Kuhn W and Muller T. (Therapy of Parkinson disease. 2: New therapy concepts for treating motor symptoms). Fortschr Neurol Psychiatr, 1997; 65: 375-385.
194. Morris MS. Homocysteine and Alzheimer’s disease. Lancet Neurol, 2003; 2: 425-428.
195. Rogers JD, Sanchez-Saffon A, Frol AB, and Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol, 2003; 60: 59-64.
196. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, and Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 2003; 60: 1125-1129.
197. Lim SY and Suzuki H. Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. J Nutr, 2000; 130: 1629-1632.
198. Carrie I, Smirnova M, Clement M, De JD, Frances H, and Bourre JM. Docosahexaenoic acid-rich phospholipid supplementation: effect on behavior, learning ability, and retinal function in control and n-3 polyunsaturated fatty acid deficient old mice. Nutr Neurosci, 2002; 5: 43-52.
199. Filburn CR. Dietary supplementation with phospholipids and docosahexaenoic acid for age-related cognitive impairment. JANA, 2000; 3: 45-55.
200. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N, Jr., Ashe KH, Frautschy SA, and Cole GM. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron, 2004; 43: 633-645.
201. Boyd WD, Graham-White J, Blackwood G, Glen I, and McQueen J. Clinical effects of choline in Alzheimer senile dementia. Lancet, 1977; 2: 711.
202. Little A, Levy R, Chuaqui-Kidd P, and Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 1985; 48: 736-742.
203. Alvarez XA, Mouzo R, Pichel V, Perez P, Laredo M, Fernandez-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano, R and Cacabelos R. Double-blind placebocontrolled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol, 1999; 21: 633-644.
204. Cacabelos R, Caamano J, Gomez MJ, Fernandez-Novoa L, Franco-Maside A, and Alvarez XA. Therapeutic effects of CDP-choline in Alzheimer’s disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann NY Acad Sci, 1996; 777: 399-403.
205. Franco-Maside A, Caamano J, Gomez MJ, and Cacabelos R. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer’s disease. Methods Find Exp Clin Pharmacol, 1994; 16: 597-607.
206. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther, 2003; 25: 178-193.
207. Secades JJ and Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol, 1995; 17(Suppl B): 1-54.
208. Amenta F, Parnetti L, Gallai V, and Wallin A. Treatment of cognitive dysfunction associated with Alzheimer’s disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Ageing Dev, 2001; 122: 2025-2040.
209. Suzuki S, Yamatoya H, Sakai M, Kataoka A, Furushiro M, and Kudo S. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine improves memory impairment in aged rats. J Nutr, 2001; 131: 2951-2956.
210. Rebouche CJ. Carnitine function and requirements during the life cycle. FASEB J, 1992; 6: 3379-3386.
211. Costell M, O’Connor JE, and Grisolia S. Age-dependent decrease of carnitine content in muscle of mice and humans. Biochem Biophys Res Commun, 1989; 161: 1135-1143.
212. Maccari F, Arseni A, Chiodi P, Ramacci MT, and Angelucci L. Levels of carnitines in brain and other tissues of rats of different ages: effect of acetyl-L-carnitine administration. Exp Gerontol, 1990; 25: 127-134.
213. Liu J, Atamna H, Kuratsune H, and Ames BN. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann NY Acad Sci, 2002; 959: 133-166.
214. Calvani M, Carta A, Caruso G, Benedetti N, and Iannuccelli M. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer’s disease. Ann NY Acad Sci, 1992; 663: 483-486.
215. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, and McClure RJ. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease. Neurobiol Aging, 1995; 16: 1-4.
216. Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol, 1986; 24: 511-516.
217. Sano M, Bell K, Cote L, Dooneief G, Lawton A, Legler L, Marder K, Naini A, Stern Y, and Mayeux R. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer’s disease. Arch Neurol, 1992; 49: 1137-1141.
218. Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, Tettamanti M, Frattura L, Tiraboschi P, Comelli M, and et al. Long-term acetyl-L-carnitine treatment in Alzheimer’s disease. Neurology, 1991; 41: 1726-1732.
219. Montgomery SA, Thal LJ, and Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol, 2003; 18: 61-71.
220. Hudson S and Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev, 2003; CD003158.
221. Mazzio E, Yoon KJ, and Soliman KF. Acetyl-L-carnitine cytoprotection against 1-methyl-4-phenylpyridinium toxicity in neuroblastoma cells. Biochem Pharmacol, 2003; 66: 297-306.
222. Bodis-Wollner I, Chung E, Ghilardi MF, Glover A, Onofrj M, Pasik P, and Samson Y. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J Neural Transm Park Dis Dement Sect, 1991; 3: 63-72.
223. Moini H, Packer L, and Saris NE. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol, 2002; 182: 84-90.
224. Packer L, Roy S, and Sen CK. Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol, 1997; 38: 79-101.
225. Packer L, Tritschler HJ, and Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med, 1997; 22: 359-378.
226. Packer L, Witt EH, and Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med, 1995; 19: 227-250.
227. Evans JL and Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther, 2000; 2: 401-413.
228. Ziegler D and Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes, 1997; 46(Suppl 2): S62-S66.
229. Hager K, Marahrens A, Kenklies M, Riederer P, and Munch G. Alpha-lipoic acid as a new treatment option for Azheimer type dementia. Arch Gerontol Geriatr, 2001; 32: 275-282.
230. Zhang L, Xing GQ, Barker JL, Chang Y, Maric D, Ma W, Li BS, and Rubinow DR. Alpha-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci Lett, 2001; 312: 125-128.
231. Hagen TM, Vinarsky V, Wehr CM, and Ames BN. (R)-alpha-lipoic acid reverses the age-associated increase in susceptibility of hepatocytes to tert-butylhydroper-oxide both in vitro and in vivo. Antioxid Redox Signal, 2000; 2: 473-483.
232. Lovell MA, Xie C, Xiong S, and Markesbery WR. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis, 2003; 5: 229-239.
233. Gao X, Dinkova-Kostova AT, and Talalay P. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc Natl Acad Sci USA, 2001; 98: 15221-15226.
234. Suh JH, Dixon BM, Liu HC, Jaiswal A, Liu R-M, and Hagen TM. The age-related decline in glutathione synthetic capacity is due to lower Nrf2-dependent gene transcription: improvement by lipoic acid. PNAS, 2004; 101: 3381-3386.
235. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, and Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA, 2001; 98: 3410-3415.
236. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, and O’Callaghan JP. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease. FASEB J, 2002; 16: 1474-1476.
237. Zhang WJ and Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J, 2001; 15: 2423-2432.
238. Bharath S, Cochran BC, Hsu M, Liu J, Ames BN, and Anderson AJ. Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: Implications for Parkinson’s Disease therapy. Neurotoxicology, 2002; 23: 479-486.
239. Frei B, Kim MC, and Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci USA, 1990; 87: 4879-4883.
240. Ernster L, Ubiquinol as a biological antioxidant: A review, In: Oxidative Processes andAntioxidants, R Paaaoletti, Ed. New York: Raven Press, Ltd, 1994: 185-198.
241. Ames BN. A role for supplements in optimizing health: the metabolic tune-up. Arch Biochem Biophys, 2004; 423: 227-234.
242. Beal MF, Matthews RT, Tieleman A, and Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res, 1998; 783: 109-114.
243. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, and Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol, 2002; 59: 1541-1550.
244. Battino M, Bompadre S, Leone L, Devecchi E, Degiuli A, D’Agostino F, Cambie G, D’Agostino M, Faggi L, Colturani G, Gorini A, and Villa RF. Coenzyme Q, vitamin E and Apo-E alleles in Alzheimer disease. Biofactors, 2003; 18: 277-281.
245. de Bustos F, Molina JA, Jimenez-Jimenez FJ, Garcia-Redondo A, Gomez-Escalonilla C, Porta-Etessam J, Berbel A, Zurdo M, Barcenilla B, Parrilla G, Enriquez-de-Salamanca R, and Arenas J. Serum levels of coenzyme Q10 in patients with Alzheimer’s disease. J Neural Transm, 2000; 107: 233-239.
246. Rae C, Digney AL, McEwan SR, and Bates TC. Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Proc R Soc Lond B Biol Sci, 2003; 270: 2147-2150.
247. Prasad KN, Cole WC, and Prasad KC. Risk factors for Alzheimer’s disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J Am Coll Nutr, 2002; 21: 506-522.
248. Hongu N and Sachan DS. Caffeine, carnitine and choline supplementation of rats decreases body fat and serum leptin concentration as does exercise. J Nutr, 2000; 130: 152-157.
249. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, and Ames BN. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci USA, 2002; 99: 2356-2361.
250. Veurink G, Liu D, Taddei K, Perry G, Smith MA, Robertson TA, Hone E, Groth DM, Atwood CS, and Martins RN. Reduction of inclusion body pathology in ApoE-defi-cient mice fed a combination of antioxidants. Free Radic Biol Med, 2003; 34: 1070-1077.
251. Shea TB, Ekinci FJ, Ortiz D, Wilson TO, and Nicolosi RJ. Efficacy of vitamin E, phosphatidyl choline and pyruvate on Abeta neurotoxicity in culture. J Nutr Health Aging, 2003; 7: 252-255.
252. Shea TB, Ekinci FJ, Ortiz D, Dawn-Linsley M, Wilson TO, and Nicolosi RJ. Efficacy of vitamin E, phosphatidyl choline, and pyruvate on buffering neuronal degeneration and oxidative stress in cultured cortical neurons and in central nervous tissue of apolipoprotein E-deficient mice. Free Radic Biol Med, 2002; 33: 276-282.
253. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, and White LR. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology, 2000; 54: 1265-1272.
254. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, and Breteler MM. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA, 2002; 287: 3223-3229.
255. Laurin D, Foley DJ, Masaki KH, White LR, and Launer LJ. Vitamin E and C supplements and risk of dementia. JAMA, 2002; 288: 2266-2268.
256. Bianchetti A, Rozzini R, and Trabucchi M. Effects of acetyl-L-carnitine in Alzheimer’s disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin, 2003; 19: 350-353.
257. Holford NH and Peace K. The effect of tacrine and lecithin in Alzheimer’s disease. A population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol, 1994; 47: 17-23.
258. Kozlov AV, Gille L, Staniek K, and Nohl H. Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch Biochem Biophys, 1999; 363: 148-154.
259. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, and Gilfix BM. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA, 1995; 92: 12260-12264.
260. Raber J, Wong D, Yu GQ, Buttini M, Mahley RW, Pitas RE, and Mucke L. Apolipoprotein E and cognitive performance. Nature, 2000; 404: 352-354.
261. Raffai RL and Weisgraber KH. Cholesterol: from heart attacks to Alzheimer’s disease. J Lipid Res, 2003; 44: 1423-1430.
262. Kritchevsky D and Moyer AW. Anti-cholesterol activity of alpha-lipoic acid. Nature, 1958; 182: 396.
263. Angelucci L and Mascitelli-Coriandoli E. Anticholesterol activity of alpha-lipoic acid. Nature, 1958; 181: 911-912.
264. Jayanthi S and Varalakshmi P. Tissue lipids in experimental calcium oxalate lithi-asis and the effect of DL alpha-lipoic acid. Biochem Int, 1992; 26: 913-921.
265. Aureli T, Di Cocco ME, Capuani G, Ricciolini R, Manetti C, Miccheli A, and Conti F. Effect of long-term feeding with acetyl-L-carnitine on the age-related changes in rat brain lipid composition: a study by 31P NMR spectroscopy. Neurochem Res, 2000; 25: 395-399.
266. Ruggiero FM, Cafagna F, Gadaleta MN, and Quagliariello E. Effect of aging and acetyl-L-carnitine on the lipid composition of rat plasma and erythrocytes. Biochem Biophys Res Commun, 1990; 170: 621-626.
267. Willis RA, Folkers K, Tucker JL, Ye CQ, Xia LJ, and Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA, 1990; 87: 8928-8930.
268. Henkel J. Attacking AIDS with a ‘cocktail’ therapy? FDA Consum, 1999; 33: 12-17.
269. Randall P. Study confirms that protease inhibitor cocktail can delay HIV disease progression and death. NIAID AIDS Agenda, 1-2, 1997.
270. Jiamton S, Pepin J, Suttent R, Filteau S, Mahakkanukrauh B, Hanshaoworakul W, Chaisilwattana P, Suthipinittharm P, Shetty P, and Jaffar S. A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV-infected individuals living in Bangkok. Aids, 2003; 17: 2461-2469.
271. Ames BN. Micronutrients prevent cancer and delay aging. Toxicol Lett, 1998; 102-103: 5-18.
272. Ames BN. Delaying the mitochondrial decay of aging-a metabolic tune-up. Alzheimer Dis Assoc Disord, 2003; 17(Suppl 2): S54-S57.
273. Wolf CR. Chemoprevention: increased potential to bear fruit. Proc Natl Acad Sci USA, 2001; 98: 2941-2943.
274. Link CD. Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech Ageing Dev, 2001; 122: 1639-1649.
275. Price DL, Tanzi RE, Borchelt DR, and Sisodia SS. Alzheimer’s disease: genetic studies and transgenic models. Annu Rev Genet, 1998; 32: 461-493.
276. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, and Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer’s disease. J Neurosci, 1996; 16: 5795-5811.
277. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, Mucke L, and Mahley RW. Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/-mice: isoform-specific effects on neurodegeneration. J Neurosci, 1999; 19: 4867-4880.
278. Raber J, Akana SF, Bhatnagar S, Dallman MF, Wong D, and Mucke L. Hypothalamic-pituitary-adrenal dysfunction in Apoe(-/-) mice: possible role in behavioral and metabolic alterations. J Neurosci, 2000; 20: 2064-2071.
279. Link CD, Taft A, Kapulkin V, Duke K, Kim S, Fei Q, Wood DE, and Sahagan BG. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer’s disease model. Neurobiol Aging, 2003; 24: 397-413.
280. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, and Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science, 2001; 293: 711-714.
281. Buttini M, Yu GQ, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, and Mucke L. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci, 2002; 22: 10539-10548.
282. White HL and Scates PW. Acetyl-L-carnitine as a precursor of acetylcholine. Neurochem Res, 1990; 15: 597-601.
283. Liu J and Ames BN, Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer’s disease and Parkinson’s disease, 2005; 8: 67-89.